XML 62 R53.htm IDEA: XBRL DOCUMENT v3.21.1
Asset Acquisition of Razor Genomics, Inc. - Schedule of Condensed Statement of Operations (Details) - USD ($)
$ in Thousands
 2 Months Ended 3 Months Ended
Feb. 23, 2021
Mar. 31, 2021
Mar. 31, 2020
Research and development expense   $ 3,361 $ 2,159
General and administrative expense   4,764 4,625
Loss from operations   (11,360) (8,431)
Net loss   $ (3,919) $ (7,732)
Razor Genomics, Inc. [Member]      
Research and development expense [1] $ 125    
General and administrative expense [1]    
Loss from operations [1] (125)    
Net loss [1] $ (125)    
[1] The condensed standalone statement of operations of Razor is provided for informational purposes only. Razor's results for the period from January 1, 2021 through February 23, 2021 are not included in Oncocytes consolidated results of operations because Razor was not consolidated with Oncocytes financial statements but had been accounted for under the equity method of accounting since the September 30, 2019 Initial Closing date, however, Oncocytes results included its pro rata losses from Razor. Beginning on February 24, 2021, Razor's results are included with Oncocytes consolidated results, primarily consisting of outside research and development expenses incurred by Razor for the Clinical Trial discussed above.